Literature DB >> 6534892

d-Fenfluramine and salbutamol: two drugs causing anorexia through different neurochemical mechanisms.

S Garattini, R Samanin.   

Abstract

Recent studies on some neurochemical and functional effects of d-fenfluramine and salbutamol in rats were summarized. It was found that d-fenfluramine releases serotonin almost exclusively from a reserpine-sensitive pool, but this is not the only mechanism by which it reduces food intake, as reserpine did not change its anorectic activity. The fact that d-norfenfluramine, the active metabolite of d-fenfluramine, uses mainly a reserpine-insensitive pool may help explain the failure of reserpine to reduce d-fenfluramine's effect on food intake. On the other hand, metergoline and chlorimipramine significantly reduced the effect of d-fenfluramine suggesting that drug's uptake into serotonin-confining neurons and serotonin release are important for the anorectic activity. The ability of d-fenfluramine to enhance serotonin function leads to a pattern of effects on various forms of eating that distinguishes this drug from d-amphetamine. In particular, studies with food-rewarded runway behaviour have clearly shown that d-fenfluramine reduces motivation for food whereas no such effect is clear for d-amphetamine. Salbutamol, a beta-adrenergic stimulant, was shown to reduce food intake in rats in a dose-dependent manner through a mechanism which seems to involve beta-adrenergic sites in the brain. The mechanism of action of salbutamol seems to be different from that of d-amphetamine since no cross-tolerance between the two drugs was found as regards their anorectic activity. Moreover, salbutamol and d-amphetamine affected differently some aspects of feeding behaviour in rats.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6534892

Source DB:  PubMed          Journal:  Int J Obes


  2 in total

Review 1.  Dexfenfluramine. Its place in weight control.

Authors:  P Turner
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.